Recently, positive safety data from phase 2 trial with anti-C5a antibody vilobelimab in patients with AAV (IXCHANGE - NCT03895801) were reported (tml, https://www.inflarx.de/Home/Investors/Press-Releases/11-2021-InflaRx-Announces-Positive-Data-from-Phase-II-IXCHANGE-Study-with-Vilobelimab-in-ANCA-associated-Vasculitis--AAV-.html, https://www.inflarx.de/Home/Investors/Press-Releases/11-2021-InflaRx-Announces-Positive-Data-from-Phase-II-IXCHANGE-Study-with-Vilobelimab-in-ANCA-associated-Vasculitis–AAV-.html ). Here, C5AR1 is linked to vasculitis.